Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	19.69	88.71	76.21	110.89	108.01	184.43
Short-Term Investments	1,547	692.82	578.28	292.74	268.39	183.36
Cash & Short-Term Investments	1,567	781.52	654.48	403.63	376.4	367.79
Cash Growth	74.03%	19.41%	62.15%	7.23%	2.34%	16.58%
Accounts Receivable	8.56	6.82	-	-	1.41	10.26
Other Current Assets	95.97	162.29	40.99	12.85	27.49	6.55
Total Current Assets	1,671	950.64	695.47	416.47	405.3	384.6
Net Property, Plant & Equipment	428.97	426.41	431.56	335.56	168.59	66.02
Other Intangible Assets	5.59	6.86	2.56	10.26	11.96	13.66
Long-Term Investments	-	-	-	-	105.87	245.6
Other Long-Term Assets	6.05	1.39	4.48	3.26	0.22	0.27
Total Assets	2,112	1,385	1,140	765.55	691.94	710.15

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Accounts Payable	27.78	17.67	11.39	35.87	2.87	9.46
Accrued Expenses	109.63	117.31	85.01	57.73	59.11	23.77
Short-Term Debt	40	40	-	-	-	-
Current Portion of Leases	5.32	7.29	6.34	10.56	2.78	2.25
Unearned Revenue	94.6	2.4	-	0.87	74.1	111.06
Other Current Liabilities	6.02	10.81	0.43	0.44	-	-
Total Current Liabilities	283.35	195.49	103.17	105.46	138.85	146.54
Long-Term Debt	1,217	582.28	734.54	268.33	-	-
Long-Term Leases	114.3	104.11	111.03	104.61	78.8	23.3
Other Long-Term Liabilities	31.74	-	-	-	55.95	131.5
Total Long-Term Liabilities	1,363	686.39	845.57	372.93	134.75	154.79
Total Liabilities	1,646	881.88	948.74	478.39	273.6	301.33

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Common Stock	0.24	0.23	0.22	0.2	0.2	0.2
Treasury Stock	-53.19	-53.19	-	-	-	-
Additional Paid-in Capital	2,443	2,140	1,806	1,300	1,219	1,053
Accumulated Other Comprehensive Income	-1.23	6.44	2	-3.22	-0.14	-0.07
Retained Earnings	-1,923	-1,627	-1,626	-1,026	-820.76	-644.69
Total Common Shareholders' Equity	465.53	466.05	182.69	271.34	398.52	408.82
Minority Interest	0.51	37.36	8.37	15.82	19.82	-
Shareholders' Equity	466.04	503.42	191.06	287.16	418.34	408.82
Total Liabilities & Equity	2,112	1,385	1,140	765.55	691.94	710.15

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Total Debt	1,376	733.68	851.91	383.5	81.58	25.55
Net Cash (Debt)	190.68	47.84	-197.43	20.13	294.82	342.24
Net Cash Growth	1.92%	-	-	-93.17%	-13.86%	16.27%
Net Cash Per Share	1.36	0.36	-1.65	0.19	2.80	3.30
Book Value	465.53	466.05	182.69	271.34	398.52	408.82
Book Value Per Share	3.32	3.48	1.53	2.54	3.78	3.94
Tangible Book Value	459.94	459.19	180.13	261.08	386.56	395.16
Tangible Book Value Per Share	3.28	3.43	1.50	2.45	3.67	3.81

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Aug 4, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 11, 2026

Data Sources Report a data error